InsiderTrades

Form 4 for FDMT 4D Molecular Therapeutics, Inc.

Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001567619-23-004430 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-03-03 2023-03-01 FDMT Bizily Scott Chief Legal, HR Off M - OptEx $6.49 +1,875 4,357 +76% +$12.2K
D 2023-03-03 2023-03-01 FDMT Bizily Scott Chief Legal, HR Off S - Sale+OE $19.30 -2,248 2,109 -52% -$43.4K
D 2023-03-03 2023-03-01 FDMT Bizily Scott Chief Legal, HR Off M - OptEx $0.00 -1,875 20.2K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-01 M A 1,875 $6.49 4,357 D — —
2 Common Common Stock 2023-03-01 S D 2,248 $19.30 2,109 D — —
3 Derivative Stock Option (Right to Buy) 2023-03-01 M D 1,875 $0.00 20,250 D $6.49 · — to 2032-06-17 1,875 Common Stock (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.